Inventor

William C. Fanslow, III

Inventor

Federal Way, WA, US

Overview

58→

Patents

1993–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 58 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides31%

A61KPreparations for medical, dental or toiletry purposes30%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%

C12NMicroorganisms or enzymes12%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%

G01NInvestigating or analysing materials by determining their chemical or physical properties2%

A01KAnimal husbandry2%

A61NElectrotherapy1%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%

PatentTitleYear

11,124,570Anti-PD1 and anti-CTLA4 antibodies2021 10,919,975Anti-mesothelin binding proteins2021 10,465,009BCMA antigen binding proteins2019 10,266,604CD27L antigen binding proteins2019 10,220,090BCMA Antigen binding proteins2019 10,100,121Anti-mesothelin binding proteins2018 9,574,008'CD27L antigen binding proteins'2017 9,243,058'BCMA antigen binding proteins'2016 8,987,422'CD27L antigen binding proteins'2015 8,414,895'Tweak receptor'2013 8,410,252'ULBP2 polypeptides'2013 7,833,697'Endothelial stem cells, populations, methods of isolation and use thereof'2010 7,829,675'TWEAK receptor'2010 7,807,796'ULBP antibodies'2010 7,741,115'Antibodies that bind LDCAM'2010 7,659,385'Polynucleotides encoding molecules designated LDCAM'2010 7,495,086'TWEAK receptor'2009 7,449,555'Antibodies of angiogenesis inhibiting domains CD148'2008 7,432,237'Methods of treating asthma by administering interleukin-17 receptor'2008 7,427,669'ULBP antibodies'2008 7,405,270'CD40-Ligand lacking native-pattern glycosylation'2008 7,402,655'Molecules designated LDCAM'2008 7,309,489'Mouse CD40 ligand-specific antibodies and hybridomas'2007 7,273,843'Methods of treating allergy by administering interleukin-17 receptor'2007 7,193,058'ULBP antibodies'2007 7,175,849'Nectin polypeptides'2007 7,074,408'Use of integrin antagonists to inhibit angiogenesis'2006 7,067,475'Tek antagonists'2006 6,774,224'ULBP DNA and polypeptides'2004 6,762,030'Ligand for CD7 and methods for use thereof'2004 6,680,057'Methods of treating autoimmune disease by administering interleukin-17 receptor'2004 6,653,447'ULBP DNA and polypeptides'2003 6,613,320'Defective CD4T-cells that express active CD40-L'2003 6,521,424'Recombinant expression of Tek antagonists'2003 6,458,350'ULBP DNA and polypeptides'2002 6,410,711'DNA encoding CD40 ligand, a cytokine that binds CD40'2002 6,391,637'Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells'2002 6,290,972'Method of augmenting a vaccine response by administering CD40 ligand'2001 6,264,951'Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L'2001 6,197,525'Assay kits for detection and methods of inhibiting IL-17 binding'2001 6,191,104'Methods of treating graft rejection with the IL-17 receptor'2001 6,106,832'Treatment of individuals exhibiting defective CD40L'2000 6,100,235'Methods of treating immune and inflammatory response with IL-17 receptors'2000 6,096,305'Receptor that binds IL-17'2000 6,087,329'CD40 ligand polypeptide'2000 6,072,033'Receptor that binds IL-17'2000 6,072,037'Antibodies to the IL-17 receptor'2000 5,981,724'DNA encoding CD40 ligand, a cytokine that binds CD40'1999 5,961,974'Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same'1999 5,962,406'Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same'1999 5,900,238'Vaccine delivery system'1999 5,869,286'Receptor that binds IL-17'1999 5,801,227'Antibodies to CD40'1998 5,783,665'Cytokine which is a ligand for OX40'1998 5,674,492'Method of preventing or treating disease characterized by neoplastic cells expressing CD40'1997 5,565,321'Detection of mutations in a CD40 ligand gene'1996 5,457,035'Cytokine which is a ligand for OX40'1995 5,223,605'Interleukin-4 binding protein-.gamma.'1993

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1993–2013Patents assigned to IMMUNEX CORP (46)· patent assignee history

1993–2008Based in Federal Way, WA, US· patent location history

2002–2021Based in Normandy Park, WA, US· patent location history

2004–2010Based in Seattle, WA, US· patent location history

2008–2021Patents assigned to AMGEN INC (9)· patent assignee history

2013Patents assigned to FANSLOW III WILLIAM C (2)· patent assignee history

2013Patents assigned to ARMITAGE RICHARD J (1)· patent assignee history

2013Patents assigned to COSMAN DAVID J (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
IMMUNEX CORP	46	1993–2013
AMGEN INC	9	2008–2021
FANSLOW III WILLIAM Cself	2	2013
ARMITAGE RICHARD J	1	2013
COSMAN DAVID J	1	2013

Locations

Location	Patents	Span
Federal Way, Washington, US	27	1993–2008
Normandy Park, Washington, US	25	2002–2021
Seattle, Washington, US	6	2004–2010